DrugPatentWatch - Biopharmaceutical Business Intelligence
Profile for Acceleron Pharma Inc. (XLRN)
« Back to company indexXLRN Chatter Timeline
Stock Ticker for XLRN
Most Active Tweeters for XLRN
| User | Tweets |
|---|---|
| @TickerReport | 4 |
| @AmericanBanking | 2 |
| @WatchlistN | 2 |
| @dailypoliticaln | 2 |
| @dailymailtimes | 2 |
Recent Tweets for XLRN
 |
@bbnsnews $27.14 Million in Sales Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/H7UQfRy5rs July 13th 2019, 6:07pm |
 |
@InsiderAlertsIA $XLRN: New Insider Filing on EVP, Chief Business Officer JOHN D QUISEL: https://t.co/uSCAR0CVWt July 11th 2019, 4:07pm |
 |
@confcalltran EVP of ACCELERON PHARMA INC just picked up 8,908 shares https://t.co/ObAEMl4umq $XLRN July 11th 2019, 4:07pm |
 |
@Clover_Research $XLRN someone will eventually figure out it’ll be more cost effective to buy Acceleron out. https://t.co/kdKjcBfnol July 11th 2019, 2:07pm |
 |
@TickerReport Acceleron Pharma Inc $XLRN Expected to Announce Quarterly Sales of $27.14 Million https://t.co/EJFYuVJWcy July 11th 2019, 9:07am |
|
@TickerReport Analysts Expect Acceleron Pharma Inc $XLRN to Post -$0.24 EPS https://t.co/EvjLIrBu6J July 9th 2019, 8:07am |
 |
@SwingTradeBot Recent $XLRN technical alerts: Stochastic Sell Signal plus 2 more alerts... https://t.co/9CITuDOmfh July 8th 2019, 12:07pm |
 |
@1MinuteStock We calculated 21-day Expected Return of $XLRN for you: 4.29% https://t.co/mSN1RwNHIq July 8th 2019, 12:07pm |
|
@1MinuteStock Btw, Estimated #Earnings Per Share for $XLRN is $-0.64 it's -1.53% of the current price https://t.co/wB8VJQrjbz July 8th 2019, 12:07pm |
 |
@midetimes Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/SrbdadTdlm #stocks July 7th 2019, 7:07pm |
 |
@dailypoliticaln Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/tYUxm8M5H0 July 7th 2019, 7:07pm |
 |
@dailymailtimes Acceleron Pharma Inc $XLRN Receives Consensus Rating of “Buy” from Brokerages https://t.co/y1SRRd2Rta #investing July 7th 2019, 7:07pm |
 |
@ZolmaxNews Analysts Set Acceleron Pharma Inc $XLRN Price Target at $61.22 https://t.co/ngaU3SMVpP July 7th 2019, 7:07pm |
 |
@AmericanBanking Acceleron Pharma Inc $XLRN Expected to Announce Quarterly Sales of $27.14 Million https://t.co/abPI44mSG8 #stocks July 6th 2019, 1:07am |
 |
@WatchlistN Acceleron Pharma Inc $XLRN Given Consensus Recommendation of “Buy” by Analysts https://t.co/KGqByCp2gg July 5th 2019, 6:07pm |
|
@SwingTradeBot Recent $XLRN technical alerts: Upper Bollinger Band Walk plus 7 more alerts... https://t.co/9CITuDOmfh July 5th 2019, 3:07pm |
 |
@FlashAlert_me $XLRN filed form CT ORDER on July 05, 09:51:41 https://t.co/ZH2KYZTsWy July 5th 2019, 9:07am |
 |
@Biotech2050 RT @semodough: $XLRN $CELG company continues to work towards potential luspatercept approval. XLRN/Celgene filed the luspatercept BLA/MAA i… July 5th 2019, 7:07am |
 |
@semodough $XLRN $CELG company continues to work towards potential luspatercept approval. XLRN/Celgene filed the luspatercept… https://t.co/qUK755RI09 July 5th 2019, 7:07am |
|
@AmericanBanking Zacks: Analysts Anticipate Acceleron Pharma Inc $XLRN to Post -$0.24 Earnings Per Share https://t.co/ogdGNmP9jz #stocks July 5th 2019, 12:07am |
 |
@WKRBNews -$0.24 Earnings Per Share Expected for Acceleron Pharma Inc $XLRN This Quarter https://t.co/fxVCauildt #markets July 5th 2019, 12:07am |
|
@ZolmaxNews Zacks: Analysts Anticipate Acceleron Pharma Inc $XLRN to Post -$0.24 Earnings Per Share https://t.co/VDikFxoucZ July 5th 2019, 12:07am |
|
@midetimes Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/vH5w1b4trP #stocks July 4th 2019, 1:07am |
|
@dailymailtimes Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/8VAzw3Iy0M #investing July 4th 2019, 1:07am |
|
@dailypoliticaln Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/fnhwOgZKdK July 4th 2019, 1:07am |
|
@WatchlistN Acceleron Pharma $XLRN Earns Hold Rating from Zacks Investment Research https://t.co/iKvQogxSaq July 4th 2019, 1:07am |
 |
@WeekHerald Acceleron Pharma’s $XLRN “Hold” Rating Reiterated at Zacks Investment Research https://t.co/Ugycs0hFZG July 3rd 2019, 2:07am |
 |
@ThisLincolnian Zacks Investment Research Reiterates “Hold” Rating for Acceleron Pharma $XLRN https://t.co/n8tX3hY5fD July 3rd 2019, 2:07am |
 |
@ConsumerFeed Acceleron Pharma $XLRN Stock Rating Reaffirmed by Zacks Investment Research https://t.co/JBXrupx1iK July 2nd 2019, 1:07am |
|
@ConsumerFeed Acceleron Pharma $XLRN Stock Rating Reaffirmed by Zacks Investment Research https://t.co/R29W7i0ExM July 2nd 2019, 1:07am |
|
@TickerReport Acceleron Pharma’s $XLRN Hold Rating Reaffirmed at Zacks Investment Research https://t.co/FbjGblq1Gu July 2nd 2019, 1:07am |
|
@TickerReport Acceleron Pharma’s $XLRN Hold Rating Reaffirmed at Zacks Investment Research https://t.co/4fS2PaHnfN July 2nd 2019, 1:07am |
 |
@Gambiste1 RT @IlliniJJ: $XLRN - two 2H 2019 and two 1Q 2020 data readouts. In addition Luspatercept has 2 upcoming PDUFA dates. https://t.co/5sCO8mm… July 1st 2019, 6:07pm |
 |
@IlliniJJ $XLRN - two 2H 2019 and two 1Q 2020 data readouts. In addition Luspatercept has 2 upcoming PDUFA dates. https://t.co/5sCO8mmMDz July 1st 2019, 11:07am |
|
@AmericanBanking Acceleron Pharma Inc $XLRN Receives Average Recommendation of “Buy” from Analysts https://t.co/dz72SufLUo #stocks June 30th 2019, 7:06am |
|
@ZolmaxNews Jean George Sells 25,688 Shares of Acceleron Pharma Inc $XLRN Stock https://t.co/3TdGjtqSU6 June 30th 2019, 4:06am |
|
@TickerReport Jean George Sells 37,500 Shares of Acceleron Pharma Inc $XLRN Stock https://t.co/vzR1RET5py June 30th 2019, 4:06am |
|
@1MinuteStock Recommendation #HOLD for $XLRN with UB rating - 2.62 out of 5. https://t.co/V323QXjJDi June 28th 2019, 10:06pm |
|
@InsiderAlertsIA $XLRN: New Insider Filing on Director JEAN GEORGE: https://t.co/nT97yOiE3J June 28th 2019, 9:06pm |
 |
@insiderbuyings $XLRN new insider selling: 37500 shares. https://t.co/Ca3gOE5sTn June 28th 2019, 9:06pm |
|
@AmericanBanking Insider Selling: Acceleron Pharma Inc $XLRN Director Sells 37,500 Shares of Stock https://t.co/TmYMOVoc52 #stocks June 28th 2019, 8:06pm |
 |
@HCWCO Yesterday, $XLRN announced target enrollment achieved in PULSAR Phase 2 trial. More in today’s Morning Summary:… https://t.co/rHZx6bkrrS June 27th 2019, 3:06pm |
 |
@tradnews_ RT @AlertTrade: TREND REVERSAL UP ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room June 27th 2019, 12:06pm |
 |
@AlertTrade TREND REVERSAL UP ALERT: $XLRN Acceleron Pharma, Inc ? TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room June 27th 2019, 12:06pm |
 |
@newswelldone $XLRN: Acceleron completes enrollment in mid-stage study of sotatercept in …: https://t.co/le1ZGQIXPh June 26th 2019, 8:06am |
 |
@ToothFrank $XLRN Completes Enrollment in the PULSAR Phase 2 Trial of Sotatercept in PAH. Topline Data Q1'20 June 26th 2019, 8:06am |
 |
@MarketCurrents $XLRN - Acceleron completes enrollment in mid-stage study of sotatercept in PAH https://t.co/8Z2ojtcDoE June 26th 2019, 7:06am |
 |
@ProVesting $XLRN: Acceleron Completes Target Enrollment in the PULSAR Phase 2 …: https://t.co/qPiIdf6y9S June 26th 2019, 7:06am |
 |
@TranscriptDaily Acceleron Pharma $XLRN Upgraded to “Hold” at Zacks Investment Research https://t.co/IdSk4U7O9o June 26th 2019, 3:06am |
 |
@registrarjourn Acceleron Pharma $XLRN Upgraded to “Hold” at Zacks Investment Research https://t.co/aRMH0xl8wt June 26th 2019, 3:06am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2019. All rights reserved.